Search alternatives:
mean decrease » a decrease (Expand Search)
mg decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
e decrease » a decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 mg » 10 mg (Expand Search)
_ e » _ em (Expand Search)
mean decrease » a decrease (Expand Search)
mg decrease » a decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
e decrease » a decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 mg » 10 mg (Expand Search)
_ e » _ em (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
Decreased clonogenic capacity of U87MG and U251MG glioma cells dependent on SHG-44 concentration.
Published 2025“…<b>(B)</b> A significant decrease in the proliferative clonal capacity of U251MG colonies was observed with 50ΜM and 100ΜM SHG-44 treatment. …”
-
7
-
8
The percentage of NaCl tolerant <i>E</i>. <i>coli</i> cells retained on filters.
Published 2019Subjects: -
9
-
10
-
11
Ageing results in an abrupt decrease in overall neurogenesis in the mouse DG.
Published 2013“…See text for additional statistical details. Scale bars (D, E, G) = 50 µm; scale bar (F) = 5 µm.</p>…”
-
12
-
13
-
14
-
15
-
16
U87MG glioma cells transduced with gal-3 shRNA demonstrate decreased tumor size and growth.
Published 2014“…The delay presented for the decrease in tumor size and growth in the gal-3 shRNA cells was not due to a decreased tumor cell proliferation <i>in vitro</i> when compared to scramble shRNA cells. …”
-
17
Decrease in extracellular Zn<sup>2+</sup> in the hippocampus by zinc chelators.
Published 2013“…Region of interest was set the area surrounding the abbreviated letters, i.e., ML and SL, where zincergic (glutamatergic) synapses exist. …”
-
18
-
19
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
20